Regulatory agencies worldwide, including the European Medicines Agency (EMA) and US Federal Drug Administration (FDA), released guidance documents outlining risk-based approaches for detecting and mitigating nitrosamine presence. This phased approach includes risk assessment, confirmatory testing, and processes for marketing authorization changes if needed. <br><br>This whitepaper provides an overview of the regulatory challenges posed by the detection of nitrosamine impurities in pharmaceutical products.
By downloading this content, I agree that SGS can use my data for the purposes of dealing with my request in accordance with the SGS Online Privacy Statement. SGS may also contact me with information on webinars, news, and events, and their experts can contact me about testing solutions.